title: Effects of manidipine and delapril on serum lipids, lipoproteins, and apolipoproteins in patients with mild to moderate essential hypertension: a randomized trial with one-year follow-up.
abstract: Forty-five patients with mild to moderate essential hypertension were randomly assigned to receive 10 to 40 mg of manidipine HCl or 15 to 60 mg of delapril daily for 12 months. In the manidipine-treated group were 13 women and 5 men (mean age, 48.2 years) and in the delapril-treated group 11 women and 11 men (mean age, 53.7 years). Blood samples were taken at baseline and after 6 and 12 months of treatment and again at 2 months after treatment discontinuation. Significant reductions in blood pressure were observed in both treatment groups. The reduction in diastolic blood pressure was significantly greater in the manidipine-treated patients than in the delapril-treated patients; no significant between-groups differences in systolic blood pressure were noted. Heart rate increased significantly in the manidipine group. No changes in serum levels of total cholesterol, triglycerides, and high-density and low-density lipoprotein cholesterol were noted during or after treatment. In the manidipine group, a small but significant decrease in apolipoprotein (apo) A-I and an increase in lipoprotein(a) were found at 6 months and a significant increase in apo A-II and apo E at 12 months; in the delapril group a significant decrease in apo A-I was found at 6 months. The results indicate that both manidipine and delapril are lipid-neutral antihypertensive drugs, since neither drug greatly affected serum lipid metabolism.
authors.affiliation: Department of Internal Medicine, Fukuoka University School of Medicine, Japan.
authors.forename: K
authors.initials: K
authors.lastname: Saku
authors.forename: B
authors.initials: B
authors.lastname: Zhang
authors.forename: K
authors.initials: K
authors.lastname: Hirata
authors.forename: R
authors.initials: R
authors.lastname: Liu
authors.forename: N
authors.initials: N
authors.lastname: Sasaki
authors.forename: T
authors.initials: T
authors.lastname: Sakai
authors.forename: H
authors.initials: H
authors.lastname: Ying
authors.forename: K
authors.initials: K
authors.lastname: Arakawa
mesh_terms: D000328:Adult; D000368:Aged; D000806:Angiotensin-Converting Enzyme Inhibitors / Q000494:pharmacology*; D001053:Apolipoproteins / Q000097:blood / Q000187:drug effects*; D001794:Blood Pressure / Q000187:drug effects; D002121:Calcium Channel Blockers / Q000494:pharmacology*; D004095:Dihydropyridines / Q000494:pharmacology*; D005260:Female; D005500:Follow-Up Studies; D006339:Heart Rate / Q000187:drug effects; D006801:Humans; D006973:Hypertension / Q000097:blood* / Q000188:drug therapy; D007189:Indans / Q000494:pharmacology*; D008055:Lipids / Q000097:blood*; D008074:Lipoproteins / Q000097:blood / Q000187:drug effects*; D008297:Male; D008875:Middle Aged; D009578:Nitrobenzenes; D010879:Piperazines
chemical_list: D000806:Angiotensin-Converting Enzyme Inhibitors; D001053:Apolipoproteins; D002121:Calcium Channel Blockers; D004095:Dihydropyridines; D007189:Indans; D008055:Lipids; D008074:Lipoproteins; D009578:Nitrobenzenes; D010879:Piperazines; C054218:manidipine; C047759:delapril